Gene polymorphisms and the risk of myocardial infarction - An emerging relation
Peters, R.J.G.; Boekholdt, S.M.

Published in:
The New England journal of medicine

DOI:
10.1056/NEJMe020140

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
sibility to the idea that the rash predisposes persons to zoster. One could therefore postulate that it is preferable that children not acquire infection with wild-type VZV. The Oka or vaccine strain of VZV rarely causes rash and is associated with less zoster in children with leukemia than the natural infection. There are early indications that zoster may also occur less frequently after immunization of normal children. The choice may be between living with latent wild-type VZV that is prone to give rise to zoster and postherpetic neuralgia and being immunized with the vaccine-type virus that is less likely to give rise to either of these. The obvious preference is for successful vaccination and avoidance of wild-type VZV infection.

In the current report, the authors suggest that the number of primary vaccine failures in previous studies may have been obscured because persons with such failures were excluded from the analysis. The authors go on to comment reasonably that one cannot and should not make policy statements on the basis of a single outbreak and that it will be important to observe the experience of others. Still, this outbreak constitutes a warning signal.

A second dose of varicella vaccine, given routinely, should decrease the number of children who have primary vaccine failure and might also prevent waning immunity, if it does indeed currently occur. The best way to protect children and adults from wild-type VZV might be to give everyone two doses of vaccine; however, formal studies will be required to determine whether this approach works, as well as the cost–benefit ratio. It is noteworthy that it took the routine administration of two doses of measles vaccine to children to control measles in the United States. The time for exploring the possibility of routinely administering two doses of varicella vaccine to children seems to have arrived.

Anne A. Gershon, M.D.
Columbia University College of Physicians and Surgeons
New York, NY 10032

Dr. Gershon has reported receiving grant support from Merck and honorariums from Merck and GlaxoSmithKline.

REFERENCES
idemia, result from multiple susceptibility loci interacting with behavior and the environment. For example, data from the Framingham Study have suggested that the effect of a common polymorphism in the promoter of the hepatic lipase gene (C – 514T) is modified by nutrients. Subjects with the TT genotype had low concentrations of high-density lipoprotein cholesterol, but only if their fat intake was at least 30 percent of their total consumed energy. Similarly, the factor V Leiden mutation becomes a risk factor for thrombembolism in women who use oral contraceptives.

Polymorphism-association studies compare the prevalence of a genetic marker in persons with a given condition with the prevalence in controls. SNPs identified as relevant may point to new biologic pathways and may be used as markers of risk or to guide the selection of therapy. However, such studies do not provide evidence that the SNP has functional consequences, and in the absence of such data, the relevance of the associations remains uncertain. It is important to remember that the absence of an association between a SNP in a certain gene and a particular disease does not rule out a role for the gene itself.

The association of a SNP with a disease may result from its linkage with a nearby susceptibility locus. This nonrandom association between alleles is called linkage disequilibrium. Thus, a SNP may be a marker of susceptibility to a disease without having a causal role. Linkage disequilibrium varies among populations, and failure to replicate the findings in a different population does not refute the finding of an association. Differences in linkage disequilibrium among populations do, however, limit the value of meta-analyses of multiple association studies. The risk attributable to polymorphisms is usually low, and for the majority of polymorphisms, therapeutic consequences are a long way off, except perhaps for the possibility of genotyping before drugs are prescribed. These limitations have cast doubts on this type of study, and some biomedical journals have even adopted a policy of not publishing the results of association studies related to complex diseases.

The article by Yamada et al. in this issue of the Journal should be viewed against this background. The findings are interesting and potentially important, but the study also demonstrates the pitfalls of research on SNPs as markers of disease. The authors studied 2819 patients with myocardial infarction and 2242 controls at 15 hospitals in Japan. Controls were asymptomatic persons who were visiting the clinic and had at least one of the classic risk factors for coronary disease. The investigators compared the patients with myocardial infarction with the controls in terms of the prevalence of 112 polymorphisms in 71 candidate genes, selected on the basis of an expected change in the expression of a protein or in its function. Thus, they determined 179,402 genotypes. A two-step analysis was performed, with a screening phase involving 909 participants and a large-scale association study involving the remaining 4152. The analysis was stratified according to sex and yielded one association in men (C1019T in the connexin 37 gene) that was statistically significant (P < 0.001) and two in women (4G – 668/5G in the plasminogen-activator inhibitor type 1 gene and 5A – 1171/6A in the stromelysin-1 gene). Many SNPs that have previously been shown to be associated with coronary disease (in other ethnic groups) were not found to have a significant association with disease in this population. The authors conclude that the three SNPs predict the risk of myocardial infarction and may help target interventions for primary prevention.

The study by Yamada et al. is noteworthy because of its large size and because of the two-step analysis described above. This approach decreases the likelihood that the findings result from the play of chance. Most genetic-association studies ignore the remainder of the genome and the presence of conventional risk factors, usually because of a small sample. In the present study, an attempt was made to account for these factors.

However, there are important limitations. First, the selection of the control group is critical. Controls should represent the cohort from which the patients were derived — for example, the general population or a birth cohort. If this restriction is adhered to, the difference between the groups will be the presence or absence of disease, and genetic differences may then be related to that disease. If the control group is recruited from the general population, the SNPs found to have an association with disease may be used as markers of risk in that population. In the present study, the controls are not clearly defined. They apparently had a reason to visit the clinic, and they had at least one risk factor for myocardial infarction. The prevalence of the classic risk factors for myocardial infarction was almost identical among patients and controls. This similarity would permit the identification of SNPs that cause disease under certain conditions — for example, in smokers only. However, such identification requires separate analyses for each risk factor, and such analyses were not performed. Furthermore, because this control group was used, SNPs that predispose persons to classic risk factors, such as hypertension and diabetes, were probably eliminated from consideration in spite of being risk factors for myocardial infarction. Moreover, myocardial infarction is a heterogeneous diagnosis, and it is not clear what phenotype was studied. The definition of the phenotype that was used in this study is unusual, requiring left ventriculography and coronary angiography, and from the combined group of inpatients and outpatients, only 27 patients with myocardial infarction per
center per year were included in the study. Both the use of this definition and the small numbers of patients enrolled may indicate the presence of selection bias, with unknown effects on the results.

Finally, the odds ratios are relatively small, and one cannot rule out the possibility of unintentional bias in the study. With such large numbers of SNPs analyzed, the problems of repetitive testing arise, even with strict criteria for statistical significance. It is noteworthy that the C allele of the C1019T polymorphism in the connexin 37 gene was associated with atherosclerosis in a Taiwanese population12 and among Swedish men,13 whereas the T allele was identified as a risk factor for myocardial infarction in men in the present study. With no information on the functional role of the polymorphism, the relevance of these findings is unknown.

In conclusion, the authors are to be commended for a carefully performed study and a huge effort. The findings of the study should be used to initiate further research aimed at replication and at elucidation of the underlying mechanisms of disease. Advice to individual patients or recommendations for primary prevention cannot be based on these findings at present.

RON J.G. PETERS, M.D.
S. MATTHIAS BOEKHOLDT, M.D.
Academic Medical Center
1100 DD Amsterdam, the Netherlands

REFERENCES